Avanos Medical, Inc. (AVNS)

Avanos Medical's stock has been impacted by weak third-quarter 2025 results and a cut in guidance, leading to a slump in share prices. Avanos Medical acquired Nexus Medical to enhance its critical care portfolio. Insider selling activity has been noted, with insiders selling $165,000.00 in company stock in the past three months. Over the past year, AVNS has underperformed both the US Medical Equipment industry and the broader US Market, with its share price dropping 33%. The stock has also experienced a 58% drop over the last five years.

Information regarding demand seasonality for Avanos Medical, Inc. products and services is indicated to be available, but the specific seasonal patterns are not detailed in the provided search results.

Avanos Medical, Inc. is a medical technology company focused on developing, manufacturing, and marketing medical devices globally, operating within the Healthcare sector, specifically in the Medical Equipment industry. The company focuses on Specialty Nutrition Systems and Pain Management & Recovery, offering products like Mic-Key enteral feeding tubes, ON-Q surgical pain pumps, and COOLIEF Cooled Radiofrequency System. Avanos' solutions aim to improve patient outcomes, reduce reliance on opioids, and prevent infection.

Avanos Medical has a global presence, selling its products in over 90 countries. The company operates 8 production facilities and has offices across North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. Its headquarters are located in Alpharetta, Georgia, U.S.

Avanos Medical aims to be a trusted partner for innovation, focusing on patient-centered solutions that improve quality of life and reduce opioid usage. Its products are recognized for being clinically differentiated and aligning with the global push for non-opioid pain solutions. However, in April 2022, a voluntary field correction was issued by the company for a hospital tool, which was reported to have the potential to cause injury or even death, negatively impacting the company's brand reputation.

Avanos Medical's ownership is heavily concentrated among institutional investors, including BlackRock, Inc., The Vanguard Group, Inc., and T. Rowe Price Group, Inc. As of the 2025 fiscal year, institutional investors held approximately 95.69% of the company. More recent data from December 2025 indicates institutional ownership edged down to 0.2% from 97.7% in September 2025, with 9 institutional investors holding a position. Corporate insiders own about 4.31% of the company, with Joseph Fralin Woody being the largest individual shareholder. While there has been insider selling in the past three months, some insiders have also purchased shares in the last 24 months.